Tecan Group Stock Price

TECN Community Fair Values

• AN

  

  AnalystConsensusTarget

  Consensus Narrative from 9 Analysts

  Expansion Into South Korea And FDA Approval To Support Future High-Value Medical Device Production

  Key Takeaways Expansion into South Korea and FDA approval in Malaysia bolster Tecan's production and revenue growth potential in medical devices. Innovations in genomics and proteomics could drive demand and revenue as new technologies gain market traction.

  CHF 225.02

  FV

  28.0% undervalued intrinsic discount

  3.75%

  Revenue growth p.a.

  0users have liked this narrative

  0users have commented on this narrative

  3users have followed this narrative

  1 day ago author updated this narrative
• AN

  

  AnalystHighTarget

  Consensus Narrative from 9 Analysts

  AI Enabled Digitalization And Aging Trends Will Expand Market Demand

  Key Takeaways Tecan's ability to scale advanced device production and leverage automation uniquely positions it for outsized growth and market share gains beyond analyst expectations. Increased recurring revenues and structural cost efficiencies are set to drive margin stability, strong operating leverage, and sustainable long-term sales growth.

  CHF 351.26

  FV

  53.9% undervalued intrinsic discount

  14.30%

  Revenue growth p.a.

  0users have liked this narrative

  0users have commented on this narrative

  0users have followed this narrative

  9 days ago author updated this narrative
• AN

  

  AnalystLowTarget

  Consensus Narrative from 9 Analysts

  Mounting Regulatory And Geopolitical Risks Will Depress Future Prospects

  Key Takeaways Heightened regulatory risks, geopolitical tensions, and shifting supply chains are poised to restrict market access, elevate costs, and dampen growth prospects. Intensifying competition, technological disruption, and over-reliance on major OEM partners threaten Tecan's market share, pricing power, and long-term earnings stability.

  CHF 165.20

  FV

  1.9% undervalued intrinsic discount

  2.04%

  Revenue growth p.a.

  0users have liked this narrative

  0users have commented on this narrative

  0users have followed this narrative

  13 days ago author updated this narrative